Abstract 2739
Background
Nintedanib (Vargatef®) is an oral triple angiokinase inhibitor of VEGF-, PDGF- and FGF-receptors approved in the EU and other countries in combination with docetaxel for treatment of locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after 1st line chemotherapy. Data are sparse regarding efficacy and safety of nintedanib in adenocarcinoma pts who had been pre-treated with ICIs.
Methods
This interim analysis included 32 pts with locally advanced, metastatic or locally recurrent lung adenocarcinoma who received nintedanib and docetaxel in 3rd line following ICIs in 2nd line within the ongoing NIS VARGADO (cohort B); it updates and extends data previously presented at ESMO IO 2018.
Results
Median age was 60 years (range: 45 – 76), 21/32 pts (65.6%) were men, and 22/32 pts (68.8%) were ECOG PS0/1. 7/32 pts (21.9%) had brain metastases, and 25/32 pts (78.1%) were current or former smokers. 1st line chemotherapy treatments included pemetrexed (23/32 pts, 71.9%), cisplatin (20/32 pts, 62.5%), carboplatin (16/32 pts, 50.0%), bevacizumab (9/32 pts, 28.1%), vinorelbine (5/32 pts, 15.6%), paclitaxel (2/32 pts, 6.3%), and docetaxel (1/32 pts, 3.1%). 2nd line treatments included nivolumab (21/32 pts, 65.6%), pembrolizumab (7/32 pts, 21.9%), and atezolizumab (3/32 pts, 9.4%). Under nintedanib and docetaxel, 12/24 pts (50.0%) developed a partial response and 7/24 pts (29.2%) showed stable disease; DCR was 79.2% (19/24 pts). Median PFS was 7.1 months (95%CI 2.9 – 8.2). Treatment emergent adverse events (TEAEs) grade ≥3, serious TEAEs, and TEAEs leading to discontinuation were observed in 18/32 pts (56.3%), 16/32 pts (50.0%), and 12/32 pts (37.5%), respectively.
Conclusions
In this updated analysis, nintedanib in combination with docetaxel showed clinically relevant efficacy and an adequate safety profile in stage IIIB/IV lung adenocarcinoma pts following treatment with chemotherapy and ICIs. Data highlight the potential clinical benefit of rational treatment sequencing with anti-angiogenic therapy after ICIs.
Clinical trial identification
NCT02392455.
Editorial acknowledgement
Legal entity responsible for the study
Boehringer Ingelheim Pharma GmbH & Co. KG.
Funding
Boehringer Ingelheim Pharma GmbH & Co. KG.
Disclosure
C. Grohe: Advisory / Consultancy, Membership on advisory board: Boehringer Ingelheim. W. Gleiber: Advisory / Consultancy, Membership on advisory board: Boehringer Ingelheim. S. Krüger: Advisory / Consultancy, Membership on advisory board: Boehringer Ingelheim. M. Schulze: Advisory / Consultancy, Membership on advisory board: Boehringer Ingelheim. J. Atz: Full / Part-time employment: Boehringer Ingelheim. R. Kaiser: Full / Part-time employment: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
5444 - Analysis of the tumor microenvironment and tumor genotype through different stages of lung adenocarcinoma
Presenter: Peter Zink
Session: Poster Display session 1
Resources:
Abstract
3124 - Does Progress achieved in the Treatment of Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) reach the Elderly Population?
Presenter: Jorune Suipyte
Session: Poster Display session 1
Resources:
Abstract
5142 - Prognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701)
Presenter: Yoshihito Ohhara
Session: Poster Display session 1
Resources:
Abstract
1580 - A novel risk classification system based on nomogram scores to predict survival of patients presenting with brain metastases at the first diagnosis of NSCLC
Presenter: Pengfei Cui
Session: Poster Display session 1
Resources:
Abstract
4442 - Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Xinran Ma
Session: Poster Display session 1
Resources:
Abstract
5405 - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
Presenter: Parneet Kaur Cheema
Session: Poster Display session 1
Resources:
Abstract
1893 - SMARCA4 Deficient Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study
Presenter: Stephen Graziano
Session: Poster Display session 1
Resources:
Abstract
5582 - Exploring Resistance to Nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
Presenter: Sara Pilotto
Session: Poster Display session 1
Resources:
Abstract
1408 - DNA damage repair deficiency is associated with early resistance to crizotinib: whole-genome analysis in non-small cell lung cancer patients with ALK-fusion
Presenter: Dongyun He
Session: Poster Display session 1
Resources:
Abstract
5751 - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Presenter: Sanjay Popat
Session: Poster Display session 1
Resources:
Abstract